Skip to content

Exploratory trial about the effect of carotenoid rich carrot on intestinal environment and bioregulatory function.

Exploratory trial about the effect of carotenoid rich carrot on intestinal environment and bioregulatory function. - Exploratory trial about the effect of carotenoid rich carrot on intestinal environment and bioregulatory function.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000039911
Enrollment
30
Registered
2020-08-31
Start date
2020-08-31
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

N/A(healthy adults)

Interventions

Duration: 8 weeks Test material: Food containing carrot concentrate Dose: Two times a day Administration: Take test material before breakfast and dinner

Sponsors

Kyoto Prefectural University Of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Those who agree in writing to participate in this study. 2) Women and men aged 20 to 65 years. 3) Those who can observe the following lifestyle during the test period from one week before the start of the trial. > Do not drink green tea more than usual before starting the trial. > Do not eat foods with high polyphenol content such as chocolate. > Do not take antibiotics. > Do not use mouthwash. > Abstain from taking probiotics (mainly yogurt). > Do not eat natto more than usual before starting the trial. > No smoking. > Do not take prebiotics (dietary fiber and oligosaccharide supplements).

Exclusion criteria

Exclusion criteria: 1) Those who are under treatment of diseases (Digestive disorders) which may influence the outcome of the study. 2) Whose diet is extremely irregular 3) Those who are routinely drinking a large amount of alcohol. 4) Smokers 5) Those who are habitually exercising such as marathon. 6) Currently, exercise therapy and diet therapy are performed/ planning to under the supervision of a physician. 7) Serious heart disease [heart failure, myocardial infarction, myocarditis, etc.] ,liver disease [liver failure symptoms (fulminant hepatitis ),patients with cirrhosis of the liver, liver tumor], renal disease [nephrotic syndrome, renal failure (acute and chronic), uremia, merged, etc. hydronephrosis], cranial nerve disease, psychiatric disease, malignant tumor disease, etc. and have a problem with general condition. 8) Those who have participated in other clinical trials within before consent get one month,and those who are currently participating in other clinical trials. 9) At the physician's judgment, who it is determined that there is a possibility that either increased risk to the subject, or sufficient data not obtained.

Design outcomes

Primary

MeasureTime frame
gut microbiota(variety and ratio of bacteria in stool)

Secondary

MeasureTime frame
Defecation status (fecal properties, number of defecations), Bile acids and short-chain fatty acids in feces, Blood carotenoid concentration, Oxidative stress markers, Oxidation-modified transthyretin, Skin condition and fatigue level

Countries

Japan

Contacts

Public ContactTomohisa Takagi

Kyoto Prefectural University of Medicine Department of Gastroenterology and Hepatology

takatomo@koto.kpu-m.ac.jp075-251-5508

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026